FRMM missed EPS expectations by 114.57%
Mar 04, 2026, 11:33 AM
-0.90%
What does FRMM do
180 Life Sciences is a clinical-stage biotechnology company based in Palo Alto, California, focused on developing novel drugs for inflammatory diseases using three platforms, primarily targeting anti-TNF therapies. The company went public on June 7, 2017, and currently employs four full-time staff.
Forum Markets (FRMM) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Forum Markets's actual EPS was -$266.00, missing the estimate of $38.76 per share, resulting in a -114.57% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.